Summary of Product Characteristics
last updated on the eMC:
31/03/2011
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 31/03/2011 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.2 - Posology and method of administration
-
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
-
Change to section 4.8 - Undesirable Effects
-
Change to section 10 date of revision of the text
|
| Date of revision of text on the SPC: 22-Mar-2011 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Section 4.2 - section headings changed
Section 4.5 - 'curariform muscle relaxants' replaced with 'Neuromuscular blocking drugs and ether'
Section 4.8 - 'curariform agents' replaced with 'Neuromuscular blocking drugs or other'
Section 10 - date of revison changed to 22/03/2011
|
|
Updated on 30/07/2010 and displayed until 31/03/2011
|
Reasons for adding or updating:
|
|
|
| Date of revision of text on the SPC: |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| None provided |
|
